agilon health inc 2026年季度报告

FORM 10-Q_______________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission file number 001-40332_______________________________________________________ agilon health, inc.(Exact name of registrant as specified in its charter) Delaware 440 Polaris Parkway, Suite 550Westerville, Ohio 43082(Address of principal executive offices)(562) 256-3800(Registrant’s telephone number, including area code)(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. YesNO Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter periodthat the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Non-accelerated Filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YESNO At April30, 2026, there were 16,683,786 shares of the registrant’s $0.01 par value common stock outstanding. agilon health, inc.INDEX PART I. FINANCIAL INFORMATION Item 1.Financial Statements:Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20253Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20254Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March31, 2026 and 20255Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three Months Ended March31, 2026 and 20256Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20257Notes to the Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk36Item 4.Controls and Procedures36 PART II. OTHER INFORMATION Item 1.Legal Proceedings37Item 1A.Risk Factors37Item 2.Unregistered Sales of Equity Securities and Use of Proceeds37Item 5.Other Information38Item 6.Exhibits38Signatures40 PART I. FINANCIAL INFORMATION The condensed consolidated balance sheets include assets and liabilities of consolidated variable interest entities (“VIEs”) as agilon health, inc.,together with its consolidated subsidiaries and VIEs (the “Company”), is the primary beneficiary of these VIEs. As of March31, 2026 andDecember31, 2025, the condensed consolidated balance sheets included total assets of the Company’s consolidated VIEs totaling $1.06billion and$840.2million, respectively, and total liabilities totaling $1.23billion and $1.04billion, respectively. See Note 12 for additional details. See accompanying Notes to the Condensed Consolidated Financial Statements. (in thousands, except per share data)(unaudited) Three Months EndedMarch 31, See accompanying Notes to the Condensed Consolidated Financial Statements. For the three months ended March 31, 2026: agilon health, inc.NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1. Business Description of Business agilon health, inc., together with its consolidated subsidiaries and VIEs (the “Company”), through its partnerships andpurpose-built model, provides the necessary capabilities, capital, and business model for existing physician groups to create aMedicare-centric, globally capitated line of business. As of March31, 2026, the Company, through its contracted physician networks,provided care to approximately 426,300 Medicare Advantage members enrolled with private health plans. Additionally, the Companyparticipates in the Centers for Medicare & Medicaid Services’ (“CMS”) Accountable Care Organ